Form 4 - Statement of changes in beneficial ownership of securities (2024)

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4

FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*

Bartoszek Raymond J.

(Last)(First)(Middle)
C/O KINETA, INC.
219 TERRY AVE. N., SUITE 300
(Street)
SEATTLEWA98109
(City)(State)(Zip)
2. Issuer Name and Ticker or Trading Symbol
KINETA, INC./DE [ KA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/15/2023
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock09/15/2023P500A$2.1810,456D
Common Stock09/18/2023P2,500A$2.0812,956D
Common Stock844,478IBy RLB Holdings Connecticut LLC(1)
Common Stock1,001IBy son
Common Stock1,000IBy daughter
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The Reporting Person is a managing member of RLB Holdings, LLC ("RLB Holdings") and RLB Holdings Connecticut LLC ("RLB Connecticut") and shares voting and dispositive power over the shares held by RLB Holdings and RLB Connecticut. As such, the Reporting Person may be deemed to beneficially own such shares held by RLB Holdings and RLB Connecticut.
Remarks:
/s/ Pauline Kenny, as Attorney-in-Fact09/19/2023
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Kineta (NASDAQ:KA)
Historical Stock Chart
From Jun 2024 to Jul 2024

Kineta (NASDAQ:KA)
Historical Stock Chart
From Jul 2023 to Jul 2024

Form 4 - Statement of changes in beneficial ownership of securities (3){{bbMessage.M_Alias}}{{bbMessage.MSG_Date}}{{bbMessage.HowLongAgo}}{{bbMessage.MSG_ID}}{{bbMessage.MSG_Subject}}
  • Share on Facebook Share on Twitter Share on Email

Loading Messages....

No posts yet, be the first!No KA Message Board. Create One!See More Posts on KA Message BoardSee More Message Board Posts

Kineta Inc News

Loading Messages....

`,data() {return {tabs: [] };},created() {this.tabs = this.$children;},methods: {selectTab(selectedTab) {this.tabs.forEach(tab => {tab.isActive = (tab.name == selectedTab.name);});}}});Vue.component('tab', {template: `

`,props: {name: { required: true },selected: { default: false}},data() {return {isActive: false};},computed: {href() {return '#' + this.name.toLowerCase().replace(/ /g, '-');}},mounted() {this.isActive = this.selected;}});Vue.component('newslist', {template: `

No News, be the first to add your company releases.

`,props: {source: { required: true },rawarticles: { required: true },limit: { default: 12 }},methods: {processData: function(articles){if(articles.length > this.limit){articles = articles.slice(0, this.limit);}this.articles = articles;this.loaded = true;Vue.nextTick(function(){});},stripRedudancies: function(articles){return _.uniqBy(articles, "headline");}},data() {return {loaded: false,articles: []};},mounted() {this.processData(this.rawarticles);}});new Vue({el: '#nw-news-widget',data: {loaded: false,availableTabs: {"Press Releases": [{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/kineta-KA\/stock-news\/94157220\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1720434646,"date":"Mon Jul 08, 2024 ","time":"6:30 AM (2 days ago)","full_date":"July 8, 2024 6:30 AM","post_time":"July 08 2024","article_id":94157220,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Kineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA Biosciences","short_text":"TuHURA has an exclusive right to negotiate to acquire Kineta\u2019s KVA12123 Immuno-Oncology Drug Program Kineta will receive a $5 million Nonrefundable Payment from TuHURA KVA12123 is currently in a...","one_line_short_text":"TuHURA has an exclusive right to negotiate to acquire Kineta\u2019s KVA12123 Immuno-Oncology Drug Program Kineta will receive a $5 million...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/kineta-KA\/stock-news\/94157200\/kineta-announces-exclusivity-and-right-of-first-of","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1720434600,"date":"Mon Jul 08, 2024 ","time":"6:30 AM (2 days ago)","full_date":"July 8, 2024 6:30 AM","post_time":"July 08 2024","article_id":94157200,"source_id":"globe","media_url":null,"press_release":true},{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/kineta-KA\/stock-news\/93953620\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1717099212,"date":"Thu May 30, 2024 ","time":"4:00 PM (1 month ago)","full_date":"May 30, 2024 4:00 PM","post_time":"May 30 2024","article_id":93953620,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/kineta-KA\/stock-news\/93860103\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1715803392,"date":"Wed May 15, 2024 ","time":"4:03 PM (2 months ago)","full_date":"May 15, 2024 4:03 PM","post_time":"May 15 2024","article_id":93860103,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1\/2 VISTA-101 Clinical Trial and Corporate Activities","short_text":"Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts Favorable clinical safety and tolerability profile observed with no...","one_line_short_text":"Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts Favorable clinical...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/kineta-KA\/stock-news\/93860040\/kineta-reports-first-quarter-2024-financial-result","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1715803260,"date":"Wed May 15, 2024 ","time":"4:01 PM (2 months ago)","full_date":"May 15, 2024 4:01 PM","post_time":"May 15 2024","article_id":93860040,"source_id":"globe","media_url":null,"press_release":true},{"headline":"Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1\/2 VISTA-101 Clinical Trial","short_text":"Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts Favorable clinical safety and tolerability profile observed with no...","one_line_short_text":"Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts Favorable clinical...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/kineta-KA\/stock-news\/93620503\/kineta-reports-initial-clinical-response-data-at-a","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1712606460,"date":"Mon Apr 08, 2024 ","time":"4:01 PM (3 months ago)","full_date":"April 8, 2024 4:01 PM","post_time":"April 08 2024","article_id":93620503,"source_id":"globe","media_url":null,"press_release":true},{"headline":"Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update","short_text":"Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts in the VISTA-101 trial No dose limiting toxicities observed at any...","one_line_short_text":"Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts in the VISTA-101...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/kineta-KA\/stock-news\/93531132\/kineta-reports-full-year-2023-financial-results-an","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1711051320,"date":"Thu Mar 21, 2024 ","time":"4:02 PM (4 months ago)","full_date":"March 21, 2024 4:02 PM","post_time":"March 21 2024","article_id":93531132,"source_id":"globe","media_url":null,"press_release":true},{"headline":"KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1\/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported","short_text":"Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohortsNo dose limiting toxicities observed at any dose levelCleared fifth of...","one_line_short_text":"Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohortsNo dose limiting...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/kineta-KA\/stock-news\/93471997\/kva12123-clears-additional-cohorts-in-monotherapy","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1710244800,"date":"Tue Mar 12, 2024 ","time":"8:00 AM (4 months ago)","full_date":"March 12, 2024 8:00 AM","post_time":"March 12 2024","article_id":93471997,"source_id":"globe","media_url":null,"press_release":true},{"headline":"Kineta Announces Restructuring and Exploration of Strategic Alternatives","short_text":"SEATTLE, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer...","one_line_short_text":"SEATTLE, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/kineta-KA\/stock-news\/93389624\/kineta-announces-restructuring-and-exploration-of","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1709213400,"date":"Thu Feb 29, 2024 ","time":"8:30 AM (4 months ago)","full_date":"February 29, 2024 8:30 AM","post_time":"February 29 2024","article_id":93389624,"source_id":"globe","media_url":null,"press_release":true},{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/kineta-KA\/stock-news\/93388700\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1709208014,"date":"Thu Feb 29, 2024 ","time":"7:00 AM (4 months ago)","full_date":"February 29, 2024 7:00 AM","post_time":"February 29 2024","article_id":93388700,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form SC 13G - Statement of acquisition of beneficial ownership by individuals","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/kineta-KA\/stock-news\/93280553\/form-sc-13g-statement-of-acquisition-of-benefici","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1707943231,"date":"Wed Feb 14, 2024 ","time":"3:40 PM (5 months ago)","full_date":"February 14, 2024 3:40 PM","post_time":"February 14 2024","article_id":93280553,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form SC 13D\/A - General statement of acquisition of beneficial ownership: [Amend]","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/kineta-KA\/stock-news\/93258721\/form-sc-13d-a-general-statement-of-acquisition-o","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1707771945,"date":"Mon Feb 12, 2024 ","time":"4:05 PM (5 months ago)","full_date":"February 12, 2024 4:05 PM","post_time":"February 12 2024","article_id":93258721,"source_id":"edgar2","media_url":null,"press_release":true}],"All News": [{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/kineta-KA\/stock-news\/94157220\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1720434646,"date":"Mon Jul 08, 2024 ","time":"6:30 AM (2 days ago)","full_date":"July 8, 2024 6:30 AM","post_time":"July 08 2024","article_id":94157220,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Kineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA Biosciences","short_text":"TuHURA has an exclusive right to negotiate to acquire Kineta\u2019s KVA12123 Immuno-Oncology Drug Program Kineta will receive a $5 million Nonrefundable Payment from TuHURA KVA12123 is currently in a...","one_line_short_text":"TuHURA has an exclusive right to negotiate to acquire Kineta\u2019s KVA12123 Immuno-Oncology Drug Program Kineta will receive a $5 million...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/kineta-KA\/stock-news\/94157200\/kineta-announces-exclusivity-and-right-of-first-of","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1720434600,"date":"Mon Jul 08, 2024 ","time":"6:30 AM (2 days ago)","full_date":"July 8, 2024 6:30 AM","post_time":"July 08 2024","article_id":94157200,"source_id":"globe","media_url":null,"press_release":true},{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/kineta-KA\/stock-news\/93953620\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1717099212,"date":"Thu May 30, 2024 ","time":"4:00 PM (1 month ago)","full_date":"May 30, 2024 4:00 PM","post_time":"May 30 2024","article_id":93953620,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/kineta-KA\/stock-news\/93860103\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1715803392,"date":"Wed May 15, 2024 ","time":"4:03 PM (2 months ago)","full_date":"May 15, 2024 4:03 PM","post_time":"May 15 2024","article_id":93860103,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1\/2 VISTA-101 Clinical Trial and Corporate Activities","short_text":"Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts Favorable clinical safety and tolerability profile observed with no...","one_line_short_text":"Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts Favorable clinical...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/kineta-KA\/stock-news\/93860040\/kineta-reports-first-quarter-2024-financial-result","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1715803260,"date":"Wed May 15, 2024 ","time":"4:01 PM (2 months ago)","full_date":"May 15, 2024 4:01 PM","post_time":"May 15 2024","article_id":93860040,"source_id":"globe","media_url":null,"press_release":true},{"headline":"Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1\/2 VISTA-101 Clinical Trial","short_text":"Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts Favorable clinical safety and tolerability profile observed with no...","one_line_short_text":"Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts Favorable clinical...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/kineta-KA\/stock-news\/93620503\/kineta-reports-initial-clinical-response-data-at-a","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1712606460,"date":"Mon Apr 08, 2024 ","time":"4:01 PM (3 months ago)","full_date":"April 8, 2024 4:01 PM","post_time":"April 08 2024","article_id":93620503,"source_id":"globe","media_url":null,"press_release":true},{"headline":"Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update","short_text":"Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts in the VISTA-101 trial No dose limiting toxicities observed at any...","one_line_short_text":"Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts in the VISTA-101...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/kineta-KA\/stock-news\/93531132\/kineta-reports-full-year-2023-financial-results-an","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1711051320,"date":"Thu Mar 21, 2024 ","time":"4:02 PM (4 months ago)","full_date":"March 21, 2024 4:02 PM","post_time":"March 21 2024","article_id":93531132,"source_id":"globe","media_url":null,"press_release":true},{"headline":"KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1\/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported","short_text":"Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohortsNo dose limiting toxicities observed at any dose levelCleared fifth of...","one_line_short_text":"Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohortsNo dose limiting...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/kineta-KA\/stock-news\/93471997\/kva12123-clears-additional-cohorts-in-monotherapy","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1710244800,"date":"Tue Mar 12, 2024 ","time":"8:00 AM (4 months ago)","full_date":"March 12, 2024 8:00 AM","post_time":"March 12 2024","article_id":93471997,"source_id":"globe","media_url":null,"press_release":true},{"headline":"Kineta Announces Restructuring and Exploration of Strategic Alternatives","short_text":"SEATTLE, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer...","one_line_short_text":"SEATTLE, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/kineta-KA\/stock-news\/93389624\/kineta-announces-restructuring-and-exploration-of","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1709213400,"date":"Thu Feb 29, 2024 ","time":"8:30 AM (4 months ago)","full_date":"February 29, 2024 8:30 AM","post_time":"February 29 2024","article_id":93389624,"source_id":"globe","media_url":null,"press_release":true},{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/kineta-KA\/stock-news\/93388700\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1709208014,"date":"Thu Feb 29, 2024 ","time":"7:00 AM (4 months ago)","full_date":"February 29, 2024 7:00 AM","post_time":"February 29 2024","article_id":93388700,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form SC 13G - Statement of acquisition of beneficial ownership by individuals","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/kineta-KA\/stock-news\/93280553\/form-sc-13g-statement-of-acquisition-of-benefici","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1707943231,"date":"Wed Feb 14, 2024 ","time":"3:40 PM (5 months ago)","full_date":"February 14, 2024 3:40 PM","post_time":"February 14 2024","article_id":93280553,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form SC 13D\/A - General statement of acquisition of beneficial ownership: [Amend]","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/kineta-KA\/stock-news\/93258721\/form-sc-13d-a-general-statement-of-acquisition-o","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1707771945,"date":"Mon Feb 12, 2024 ","time":"4:05 PM (5 months ago)","full_date":"February 12, 2024 4:05 PM","post_time":"February 12 2024","article_id":93258721,"source_id":"edgar2","media_url":null,"press_release":true}],"Preferred Contributors": ""}},created: function () {this.loaded = true;Vue.nextTick(function(){});}});});

More Kineta Inc News Articles

Form 4 - Statement of changes in beneficial ownership of securities (2024)
Top Articles
Latest Posts
Article information

Author: Pres. Lawanda Wiegand

Last Updated:

Views: 6531

Rating: 4 / 5 (51 voted)

Reviews: 90% of readers found this page helpful

Author information

Name: Pres. Lawanda Wiegand

Birthday: 1993-01-10

Address: Suite 391 6963 Ullrich Shore, Bellefort, WI 01350-7893

Phone: +6806610432415

Job: Dynamic Manufacturing Assistant

Hobby: amateur radio, Taekwondo, Wood carving, Parkour, Skateboarding, Running, Rafting

Introduction: My name is Pres. Lawanda Wiegand, I am a inquisitive, helpful, glamorous, cheerful, open, clever, innocent person who loves writing and wants to share my knowledge and understanding with you.